Neeraj Adya
Head, Diagnostics, Immunology Johnson & Johnson Innovative Medicines
Seminars
Wednesday 7th October 2026
MRD in IBD? Building a Precision Medicine Consortium for Deeper Endpoints in IBD
12:40 pm
- Precision medicine transformed oncology by enabling patient segmentation, molecular monitoring, and the adoption of more sensitive endpoints such as minimal residual disease. Can inflammatory bowel disease be next?
- In this joint presentation, Johnson & Johnson Innovative Medicines and the Crohn's & Colitis Foundation explore how precision medicine and diagnostics approaches can advance IBD beyond traditional remission endpoints toward deeper measures of disease control
- The session proposes a pre-competitive consortium model that brings together industry, foundations, diagnostic developers, and data partners to standardize endpoints, harmonize biospecimen and data strategies, and accelerate the development of clinically actionable biomarkers and Rx-Dx solutions
Thursday 8th October 2026
Panel Discussion: Fit-for-Purpose CDx Strategies: Matching Testing Approaches to Development & Patient Access Needs
2:00 pm
- The CDx market is growing rapidly as precision medicine gains momentum and more targeted therapies enter clinical development
- While many pioneering biomarker programs begin in centralized laboratories, the long-term commercial vision often requires models to evolve to allow greater scalability and geographic accessibility
- This discussion will explore how sponsors are balancing scientific complexity, operational realities, and commercial goals as they navigate the transition from centralized testing toward decentralized and distributable CDx approaches
